Analysis of p53 mutation and cyclin D1 expression in breast tumors

Pathology and Oncology Research

Volumn 5, Issue 2, 1999, Pages 90-94

  Tanyi, János ^a   Tory, Kálmán ^b   Bánkfalvi, Agnes ^b   Shröder, Willibald ^c   Rath, Werner ^c   Füzesi, László ^b  

^a SEMMELWEIS UNIVERSITY OF MEDICINE   (Hungary)

^b RWTH AACHEN UNIVERSITY   (Germany)

^c UNIVERSITY HOSPITAL MÜNSTER   (Germany)

Author keywords

Breast cancer; Cyclin D1; Fibroadenoma; Immunohistochemistry; Mutation; P53

Indexed keywords

CYCLIN D1; PROTEIN P53;

ARTICLE; BREAST TUMOR; DNA DAMAGE; DNA SYNTHESIS INHIBITION; FIBROADENOMA; GENE EXPRESSION REGULATION; GENE MUTATION; GENETIC ANALYSIS; GENETIC REGULATION; GENETIC TRANSCRIPTION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; PROTEIN EXPRESSION;

EID: 0032797333     PISSN: 12194956     EISSN: None     Source Type: Journal    
DOI: 10.1053/paor.1999.0201     Document Type: Article

References (31)

1. Andersen T I, Holm R, Nesland J M. Prognostic significance of TP53 alterations in breast carcinoma. Br J Cancer. 68:1993;540-548.
2. Bates S, Parry D, Bonetta L. Absence of cyclin D/cdk complexes in cells lacking functional retinoblastoma protein. Oncogene. 9:1994;1633-1640.
3. Bankfalvi A, Navabi H, Bier B. Wet autoclave pretreatment for antigen retrieval in diagnostic immunohistochemistry. J Pathol. 174:1994;223-228.
4. Chen X, Bargonetti J, Prives C. P53, through p21 (WAF1/CIP1) induces cyclin D1 synthesis. Cancer Res. 55:1995;4257-6342.
5. Cordon-Cardo C. Mutation of cell cycle regulators. Am J Pathol. 147:1995;545-560.
6. El-Deiry W S, Tokino T, Velculescu V E. WAF1, a potential mediator of p53 tumor suppression. Cell. 75:1993;817-825.
7. Fantl V, Smith R, Brokes S. Chromosome 11q13 abnormalities in human breast cancer. Cancer Surv. 18:1993;77-94.
8. Gillett C, Smith P, Gregory W. Cyclin D1 and prognosis in human breast cancer. Int J Cancer. 69:1996;92-99.
9. Ggrana K, Reddy E P. Cell cycle control in mammalian cells: role of cyclins, cyclin dependent kinases (CDKs), growth suppressor genes and cyclin-dependent kinase inhibitors (CKIs). Oncogene. 11:1995;211-219.
10. Greenblatt M S, Bennett W P, Hollstein M. Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res. 54:1994;4855-4878.
11. Hollstein M, Sidransky D, Vogelstein B. p53 mutation in human cancers. Science. 253:1991;49-53.
12. Jacquemier J, Moles J P, Adelaide J. P53 immunohistochemical analysis in breast cancer with four monoclonal antibodies: comparison of staining and PCR-SSCP results. Br J Cancer. 89:1994;846-852.
13. Kastan M B, Zhan Q, El-Deiry W S. A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-teleangiectasia. Cell. 71:1992;587-597.
14. Kovach J S, Hartmann A, Blaszik H. Mutation detection by highly sensitive method indicates that p53 gene mutations in breast cancer can have important prognostic value. Proc Natl Acad Sci USA. 93:1996;1093-1096.
15. Kranenburg O, van der Eb A J, Zantema A. Cyclin D1 is an essential mediator of apoptotic neuronal cell death. EMBO J. 15:1996;46-54.
16. Lane D P. P53 guardien of genome. Nature. 359:1992;15-16.
17. Li Y, Jenkins C, Nichols M. Cell cycle expression and p53 regulation of the cyclin-dependent kinase inhibitor p21. Oncogene. 9:1994;2261-2268.
18. Lidereau R, Mathieu D, Escot C. Genetic variability of proto-oncogenes for breast cancer risk and prognosis. Biochemie. 70:1988;951-959.
19. Lucibello F C, Sewing A, Brusselbach S. Deregulation of cyclin D1 and E and suppression of cdk2 and cdk4 in senescenct human fibroblasts. J Cell Sci. 105:1993;123-133.
20. Matsushime H, Quelle D E, Shurtleff S A. D-type cyclin-dependent kinase activity in mammalian cells. Mol Cell Biol. 14:1994;2066-2076.
21. McIntosh G G, Anderson J J, Milton I. Determination of the prognostic value of cyclin D1 overexpression in breast cancer. Oncogene. 11:1995;885-891.
22. Michalides R, Hageman P, Tinteren H. A clinicopathological study on overexpression of cyclin D1 and p53 in a series of 248 patients with operable breast cancer. Brit J Cancer. 73:1996;728-734.
23. Schauer I E, Siriwardana S, Langan T A. Cyclin D1 overexpression vs. retinoblastoma inactivation: implications for growth control evasion in non-small cell and small cell lung cancer. Proc Natl Acad Sci USA. 91:1994;7827-7831.
24. Shuuring E, Verhoeven E, van Tinteren H. Amplification of genes within the chromosome 11q13 region is indicative of poor prognosis in patients with operable breast cancer. Cancer Res. 52:1992;5229-5234.
25. Thor A D, Moore D H, Edgerton S M. Accumulation of p53 tumor suppressor gene protein: an independent marker of prognosis in breast cancer. JNCI. 84:1992;845-855.
26. Toguchida J, Yamaguchi T, Rithchie B. Mutation spectrum of the p53 gene in bone and soft tissue sarcomas. Cancer Res. 52:1992;6194-6199.
27. Vogelstein B, Kinzler K W. P53 function and disfunction. Cell. 70:1992;523-526.
28. Waga S, Hannon G J, Beach D. The p21 inhibitor of cyclin dependent kinases controls DNA replication by interaction with PCNA. Nature. 369:1994;574-578.
29. Wang T C, Cardiff R D, Zukerberg L. Mammary hyperplasia and carcinoma in MMTV-cyclin D1 transgenic mice. Nature. 369:1994;669-671.
30. Wu X, Bayle J H, Olson D. The p53-mdm2 autoregulatory feedback loop. Genes Dev. 7:1993;1126-1132.
31. Xiong Y, Hannon G J, Zhang H. P21 is a universal inhibitor of cyclin kinases. Nature. 366:1993;701-704.